| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Proceeds from issuance of related-party promissory notes, net of issuance costs paid | - | - | - | 0 |
| Payment of revenue interest liability | - | - | 0 | - |
| Net cash provided by financing activities | 345,347 | 171,828 | -982 | 174,701 |
| Effect of exchange rate changes on cash and cash equivalents, and restricted cash | 10 | 66 | -10 | -16 |
| Net change in cash and cash equivalents, and restricted cash | -82,575 | -5,770 | -82,768 | -153,487 |
| Cash and cash equivalents at beginning of period | 143,912 | 143,912 | 143,912 | 265,787 |
| Cash and cash equivalents at end of period | 61,337 | 138,142 | 61,144 | 112,300 |
ImmunityBio, Inc. (IBRX)
ImmunityBio, Inc. (IBRX)